Paul Rachal
Family Medicine · New Roads, LANPI 1811997141
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 587 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 47 manufacturers, the largest accounting for just 14.2% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 587 payments — averaging $18.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$976
- Lilly USA, LLC$830
- Amgen$726
- AstraZeneca$692
- Pfizer$561
- plus $6K from 41 others
What the payments were for
- Food & beverage$10,819100%
- Education$490%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Jornay PM 20mg capsules (Bottle of 100)$375
- FARXIGA$232
- FREESTYLE LIBRE 3$184
- RYBELSUS$125
- Ozempic$125
- EVENITY$122
- AIRSUPRA$122
- AIMOVIG$122
- JARDIANCE$122
- EXCLUDER AAA Endoprosthesis$107
- JORNAY PM$105
How this compares
$10,867 in reported general payments places this provider in the 90th percentile of 1,469 family medicine providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 252 | $313,818 |
| MounjaroTirzepatide | 164 | $201,666 |
| JardianceEmpagliflozin | 187 | $163,657 |
| TrulicityDulaglutide | 119 | $141,555 |
| EliquisApixaban | 132 | $124,734 |
| FarxigaDapagliflozin Propanediol | 73 | $86,651 |
| VraylarCariprazine Hcl | 42 | $60,723 |
| EntrestoSacubitril/Valsartan | 55 | $51,642 |
| RybelsusSemaglutide | 37 | $50,650 |
| LinzessLinaclotide | 41 | $35,900 |
| JanuviaSitagliptin Phosphate | 29 | $31,210 |
| ProliaDenosumab | 16 | $26,391 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $19,284 |
| MyrbetriqMirabegron | 16 | $14,073 |
| JanumetSitagliptin Phos/Metformin Hcl | 19 | $10,921 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $976 | $364,468289 claims |
| Lilly USA, LLCMounjaro, Trulicity | $830 | $343,221283 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $450 | $182,322215 claims |
| PfizerEliquis | $561 | $124,734132 claims |
| AbbVieVraylar, Linzess | $1,546 | $96,62383 claims |
| AstraZenecaFarxiga, Symbicort | $692 | $94,81398 claims |
| NovartisEntresto | $43 | $51,64255 claims |
| MerckJanuvia, Janumet | $156 | $42,13148 claims |
| AmgenProlia | $726 | $26,39116 claims |
| Astellas Pharma US IncMyrbetriq | $202 | $14,07316 claims |
| Hikma Pharmaceuticals USAMitigare | $59 | $10,87219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in New Roads
- Christine SmithBaton Rouge$185K
- Thomas DansbyMonroe$169K
- Michael FlemingShreveport$165K
- Robert St AmantGonzales$156K
- William HathawaySpringhill$105K
- Cesar GonzalesWest Monroe$94K
- Phillip ConnerSulphur$71K
- Richard JeansonneMandeville$49K
- Leonard TreanorHammond$29K
- Shannon HaasMandeville$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.